IMR Press / EJGO / Volume 19 / Issue 3 / pii/1998160

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer

Show Less
1 Institute of Oncology, Department of Medical Oncology, University of Istanbul, Turkey
2 Faculty of Medicine, Department of Gynaecological Oncology, University of Istanbul, Turkey
Eur. J. Gynaecol. Oncol. 1998, 19(3), 265–270;
Published: 10 June 1998

Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (IP) route and ifosfamide 4 g/m2 (15th day) by IV route every 4 weeks for a total of 6 cycles. Pathologic complete response (pCR) was achieved in 9/20 (45%, 95% Confidence Interval - Cl - 23- 68) of the patients. The median progression free interval (PFI) of the patients with pCR was 45 (range: 18–70) months. For patients with residual tumor <l cm (n: 11); pCR was 82% and could be achieved only in this subgroup of patients. The cumulative (PFI) and overall survival rate of all patients at 3 years were 40% and 52%, respectively. The median PFI was found to be significantly dif­ferent between the patients with residual tumor <1 cm (48 months, 95% CI 42-54) and 1-2 cm (9 months, 95% CI 1-16) p < 0.001. Main toxicities were emesis and abdominal pain which occurred in 53% and 65% of the courses, respectively. This combination seems to be an effective and feasible approach to previously untreated ovarian cancer patients with minimal tumor burden.

Intraperitoneal chemotherapy
Ovarian cancer
Back to top